Previous Close | 291.92 |
Open | 292.36 |
Bid | 279.00 x 800 |
Ask | 290.66 x 2200 |
Day's Range | 289.94 - 295.89 |
52 Week Range | 187.16 - 311.88 |
Volume | |
Avg. Volume | 1,228,142 |
Market Cap | 42.611B |
Beta (5Y Monthly) | 0.17 |
PE Ratio (TTM) | 15.04 |
EPS (TTM) | 19.29 |
Earnings Date | Feb 01, 2023 - Feb 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 295.44 |
Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.
Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo. Eisai has also filed for approval of the drug in Japan.
TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of